CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx Inc.

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on CVRx, with a price target of $14.00. Takkinen covers the Hea...

Lake Street Reaffirms Their Buy Rating on CVRx (CVRX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT – Research Report), Maravai...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX)

Lake Street analyst Frank Takkinen reiterated a Buy rating on CVRx today and set a price target of $14.00. Takkinen covers the Healthcare sector, f...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CVRX	$6.55	-1.36%	202.53K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CVRX	$6.55	-1.4%	202.53K
3
4
5
6

CVRX

CVRX

Dividend Overview

Get CVRx Inc. Data in Excel

Get CVRx Inc. Data in Excel